Gilead Sciences : Ask Biography
AskBiography Logo   Latest News  Follow Us on Twitter  Follow Us on Google Buzz  Became Fan - Facebook  Subscribe to RSSRSS   Bookmark and Share

Gilead Sciences

Gilead Sciences
Company nameGilead Sciences
Company typePublic Nasdaq - GILD
IndustryHealthcare, Biotechnology, Pharmaceutical company
Founded1987
HeadquartersFoster City, California, U.S.
Key peopleJohn Martin, President and Chief Executive Officer
ProductsAmBisome, Atripla, Cayston, Emtriva, Flolan, Hepsera, Letairis, Lexiscan, Macugen, Ranexa, Tamiflu, Truvada, Viread, Vistide
RevenueUS$7.95 billion (2010)
Operating income(+)US$2.90 billion (2010)
Net income(+)US$3.96 billion (2010)
Employees4,000 (2010)

     Home | Company | Gilead Sciences



Gilead Sciences (Nasdaq - GILD) is a biopharmaceutical company that discovers, develops and commercializes therapeutics. For many years since the company was founded, the company concentrated primarily on antiviral drugs to treat patients infected with HIV, hepatitis B or influenza. In 2006, Gilead acquired two companies that were developing drugs to treat patients with pulmonary diseases. The company has fourteen commercially available products. Headquartered and founded in Foster City, California, Gilead has operations in North America, Europe and Australia. As of the end of 2009, the company had approximately 4,000 full-time employees. The company's name and logo refer to the Balm of Gilead. Gilead (a place mentioned in the Bible) was famed for its small trees that produced a resin used in medicine.

Gilead is a member of the NASDAQ Biotechnology Index and the S&P 500.

Gilead Sciences Video

Many thanks to our friends at Gilead Sciences, Inc. for allowing us to share this informational video on hepatitis B virus (English).
8.20 min. | 4.90 user rating		 To access these tools, sign up for free at www.kapitall.com This video shows you how to use Kapitall to analyze top performing stocks For this screen, we're looking at low risk companies in the S&P500 index with an average earnings growth rate of more than 10% over the last 5 years. To narrow the list down some more, we only focus on companies with expected earnings growth rates of more than 15% over the next 3-5 years. Risk ratings are assembled by Zacks Investment Research. The complete list, ranked according to the average 5 year earnings growth rate: 1. Google (GOOG): 66% historical growth, 26.18% expected growth 2. Apple (AAPL): 55.50% historical growth, 18.80% expected growth 3. Gilead Sciences (GILD): 45.10% historical growth, 15.91% expected growth 4. Express Scripts (ESRX): 29.30% historical growth, 17.31% expected growth 5. DeVry Inc (DV): 27.90% historical growth, 19.84% expected growth 6. Amphenol Corp (APH): 27.70% historical growth, 17.50% expected growth 7. Rockwell Collins (COL): 23.30% historical growth, 15.76% expected growth 8. Stericycle Inc. (SRCL): 19.00% historical growth, 18.75% expected growth 9. O'Reilly Automation (ORLY): 11.80% historical growth, 16.75% expected growth Sign up (for free): www.kapitall.com
1.50 min. | 3.66 user rating		 Many thanks to our friends at Gilead Sciences, Inc. for allowing us to share this informational video on hepatitis B virus (Việt).
9.37 min. | 5.0 user rating		 Many thanks to our friends at Gilead Sciences, Inc. for allowing us to share this informational video on hepatitis B virus (粵語).
8.55 min. | 5.0 user rating		 Gilead Sciences Chairman of the Board & CEO John Martin, Ph.D., discusses HIV treatment innovation and the the potential impact of healthcare reform.
2.55 min. | 0 user rating
Many thanks to our friends at Gilead Sciences, Inc. for allowing us to share this informational video on hepatitis B virus (한국어).
9.02 min. | 5.0 user rating		 Tamiflu is an antiviral medication used to treat influenza. It will be the prime medication sold to protect citizens from swine flu as it was for avian flu. All healthcare workers, military and essential service workers will need a dose available and it will be bought with your tax dollars.Tamiflu is made and patented by Gilead Sciences and Donald Rumsfeld was the chairman of this company before he joined the Bush administration.
2.85 min. | 4.83 user rating		 Gilead's got it going on thanks to some hiv/aids meds and the patents to go with them till 2017.
1.80 min. | 3.0 user rating		 The company's HIV franchise includes blockbuster Truvada, a combination of two of its other drugs, Viread and Emtriva. It co-promotes another HIV treatment, called Atripla, in the US and Europe with Bristol-Myers Squibb. Other products on the market include AmBisome, used to treat systemic fungal infections such as those that accompany AIDS; Vistide, for AIDS-related eye infections; and hepatitis B antiviral Hepsera. Outside of the infectious disease realm, Gilead markets Letairis, a treatment for pulmonary arterial hypertension (PAH), or high pulmonary blood pressure.
0.95 min. | 5.0 user rating		 04/05/2009 Por Influenza de Rumsfeld! :: :: jah começaram(O Globo, Veja) a falar neste medicamento, Tamiflu, para atuar contra este "novo" virus, fabricado pela Roche(o medicamento)... Mas nao falam que combate apenas os sintomas(e tao pouco que o virus eh menos maligno do que aquele de origem aviaria apenas), e um detalhe importante: * O Tamiflu até 1996 era propriedade da Gilead Sciences inc. ,empresa que vendeu a patente aos laboratórios Roche. E na ocasiao o presidente desta empresa era o secretário da Defesa dos Estados Unidos, Donald Rumsfeld, que até hoje permanece um dos principais accionistas... Em 2005, quando começou a se falar da gripe aviária, a Gilead Sciences inc desejou reaver o Tamiflu alegando que a Roche não se esforçava o suficiente para fabricá-lo e comercializá-lo. Ambas as empresas negociaram e constituiram dois comitées, um para coordenar o fabrico mundial do fármaco e decidir a autorização a terceiros para fabricá-lo e outro comitée para a comercialização de vendas estacionais nos mercados mais importantes , inclusive Estados Unidos. Além disso a Roche pagou à Gilead Sciences inc regalias retroactivas no valor de 62,5 milhões de dólares. Roche ficou com 90% da produção mundial de anis estrelado, árvore que cresce fundamentalmente na China e que se encontra também em Laos e Malásia , e que faz a base do Tamiflu . O cenário estava preparado, bastava agora encontrar pouco a pouco aves contagiadas pelo vírus em diferentes países , uma ave aqui, outra <b>...</b>
6.87 min. | 3.0 user rating

Latest News : Gilead Sciences : Tweet this RSS

Want to Gilead Sciences latest news on your twitter account???   sign in with twitter
Gilead Sciences     sign in with twitter   ||  Company     sign in with twitter   ||  Economy     sign in with twitter
Gilead Sciences to Release First Quarter 2011 Financial Results on Wednesday ... - Business Wire (press release) Tweet this news
Business Wire (press release)--(BUSINESS WIRE)---Gilead Sciences-, Inc. (Nasdaq: GILD) announced today that its first quarter 2011 financial results will be released on Wednesday, April 20, 2011, at 4:05 pm Eastern Time. At 5:30 pm Eastern Time, Gilead&ap - Date : Wed, 13 Apr 2011 20:33:12 GMT+00:00
Barclays Maintains an 'Equalweight' on Gilead Sciences (GILD); Revising ... - StreetInsider.com (subscription) Tweet this news
StreetInsider.com (subscription)---...- $4.70 vs $4.65 and 2013 estimate of $5.36 vs $5.17. Longer term we estimate 2014-2020 EPS of $5.94, $6.41, $6.84, $7.31, $7.82, $8.35 and $8.80 respectively." Shares of -Gilead Sciences- closed at $41.85 ye - Date : Fri, 15 Apr 2011 17:43:07 GMT+00:00
Watch for Shares of Gilead Sciences (GILD) to Approach Support at $41.36 - Benzinga Tweet this news
Benzinga--SmarTrend has detected shares of -Gilead Sciences- (NASDAQ: GILD) have bearishly opened below the pivot of $41.91 today and have reached the first level of support of $41.55. Should the shares continue to fall, we are monitoring the next support - Date : Thu, 07 Apr 2011 19:14:17 GMT+00:00
Updates on Healthcare Sector: GILD, SGEN, REGN - Stock Market Weekly Tweet this news
Stock Market Weekly---Gilead Sciences-, Inc. (Public, NASDAQ:GILD). Last Market Price: 41.85, Change: +0.50, % Change: (1.21%). Shares trade in the range of 40.99 - 41.87 dollars. It has a market capitalization of 33.19B dollars and has 792.97M outstandin - Date : Fri, 15 Apr 2011 13:44:22 GMT+00:00
Gilead Sciences Inc. (GILD) Chairman and CEO John C Martin sells 92320 Shares - GuruFocus.com Tweet this news
GuruFocus.com--Chairman and CEO of -Gilead Sciences- Inc. (GILD) John C Martin sells 92320 shares of GILD on 04/01/2011 at an average price of $42.5 a share. -Gilead Sciences- Inc. has a market cap of $33.18 billion; its shares were traded at around $41.8 - Date : Wed, 06 Apr 2011 02:21:12 GMT+00:00
Potential Gilead Sciences (GILD) Trade Targets 21.58% Return - Market Intelligence Center Tweet this news
Market Intelligence Center---Gilead Sciences- (NASDAQ:GILD) closed Tuesday's up-and-down trading session at $41.84. In the past year, the stock has hit a 52-week low of $31.73 and 52-week high of $46.62. -Gilead Sciences- stock has been showing suppo - Date : Wed, 06 Apr 2011 13:12:10 GMT+00:00
Yale and Gilead Sciences Sign $40 Million Pact in Search for Cancer Drugs - Wall Street Journal (blog) Tweet this news
Wall Street Journal (blog)---Gilead Sciences- and the Yale School of Medicine are joining forces in the latest collaboration between industry and academia to hunt for new drugs. Gilead, known mostly for its line of medicines for HIV/AIDS, will pay $40 mil - Date : Thu, 31 Mar 2011 20:22:44 GMT+00:00
Gilead Issues Debt That Looks Attractive for Investors - Toronto Star Tweet this news
Toronto Star--by Morningstar Credit Committee | 25 Mar 11 -Gilead Sciences- GILD announced pricing on $1 billion of senior unsecured notes this week. The notes will mature in April 2021 and bear an interest rate of 4.5%, or a spread around T+125 at issue. - Date : Fri, 25 Mar 2011 16:00:13 GMT+00:00
Rare Variants Can Cause HIV Treatment Failure - MedPage Today Tweet this news
MedPage Today--The researchers had support from Harvard, MIT Health -Sciences- and Technology, Beth Israel Deaconess Medical Center, Pfizer, Merck & Co, the NIH, the Collaborative HIV and Anti-HIV Drug Resistance Network, the Swiss National Scienc - Date : Wed, 06 Apr 2011 13:09:14 GMT+00:00
Gilead Sciences offering $1 billion in notes - BusinessWeek Tweet this news
BusinessWeek---Gilead- intends to use the proceeds from the offering for general corporate purposes, including repaying debt. Bank of America Merrill Lynch, JP Morgan and Morgan Stanley acted as joint book-running managers for the offering.--- - Date : Fri, 25 Mar 2011 11:41:10 GMT+00:00

Timetable of Mergers and Acquisitions
Timetable of mergers and acquisitions :
Year Company Price Notes
1999 Nexstar Pharmaceuticals $550 million Nexstar had two drugs (AmBisome and DaunoXome) of which only AmBisome is still in Gilead's portfolio, although it is not a major source of income for the company. DaunoXome was sold to Diatos in 2006. As important as the products, Nexstar also provided Gilead with a much-needed sales force and commercialization team in Europe and Australia, and a manufacturing plant in San Dimas, California.
2003 Triangle Pharmaceuticals $464 million Triangle owned the development and commercialization rights to emtricitabine, which although marketed as a stand-alone product (Emtriva), is also a component of the more profitable combination products Atripla and Truvada.
2006 Corus Pharma, Inc. $365 million The acquisition of Corus signaled Gilead's entry into the respiratory arena. Corus was developing aztreonam lysine for the treatment of patients with cystic fibrosis who are infected with Pseudomonas aeruginosa
2006 Myogen, Inc. $2.5 billion With two drugs in development (ambrisentan and darusentan), and one marketed product (Flolan) for pulmonary diseases, the acquisition of Myogen has solidified Gilead's position in this therapeutic arena.
2006 Raylo Chemicals, Inc. $148 million This Edmonton, Alberta site will be used for process research and for manufacturing compounds for both clinical studies and commercial products.
2007 Nycomed fr. Altana - Cork $47 million This commercial manufacturing site was purchased by Gilead in place of building out the site in Dublin. This site is formerly Altana in Cork which was purchased by Nycomed.
2009 CV Therapeutics, Inc. $1.4 billion This acquisition brings Ranexa and Lexiscan as commercial products. Ranexa is a cardiovascular drug used to treat chest pain related to coronary artery disease. These products and pipeline build out Gilead's cardiovascular franchise.
2010 CGI Pharmaceuticals $120 million This acquisition helps to broaden Gilead's research expertise into kinase biology and chemistry.
2010 Arresto Biosciences, Inc. $225 million This acquisition brings Gilead developmental-stage research for treating fibrotic diseases and cancer.
2011 Calistoga Pharmaceuticals $375 million ($225 million additional w/ milestones) Acquisition of Calistoga bolsters areas of oncology and inflammation.

Timetable of mergers and acquisitions :
Name Title
John C. Martin Chief Executive Officer and Chairman
Norbert W. Bischofberger Executive Vice President, Research and Development and Chief Scientific Officer
John F. Milligan President and Chief Operating Officer
Robin Washington Senior Vice President and Chief Financial Officer
Kevin Young Executive Vice President, Commercial Operations
Gregg H. Alton Senior Vice President and General Counsel
Anthony D. Caracciolo Senior Vice President, Manufacturing and Operations
Paul Carter Senior Vice President, International Commercial Operations
Seigo Izumo Senior Vice President, Head of Cardiovascular Therapeutics
William A. Lee Senior Vice President, Head of Antiviral Therapeutics
James R. Meyers Senior Vice President, Commercial Operations, North America
A. Bruce Montgomery Senior Vice President, Head of Respiratory Therapeutics
John J. Toole Senior Vice President, Corporate Development
Taiyin Yang Senior Vice President, Pharmaceutical Development and Manufacturing
Kristen M. Metza Senior Vice President, Human Resources

Product Portfolio
Timetable of mergers and acquisitions :
Brand Name Drug Name(s) Indication Date Approved (USA) Marketing Partner(s) U.S. Patent Expiration European Patent Expiration
AmBisome liposomal amphotericin B fungal infection, cryptococcal meningitis, Aspergillus, Candida, Cryptococcus infections 1997-08-11 Astellas Pharma(USA)Rapiscan(EU) 2016 2008
Atripla tenofovir, emtricitabine, and efavirenz HIV, AIDS 2006-07-12 Bristol-Myers Squibb 2021 2018
Cayston Aztreonam Cystic Fibrosis 2010-02-22 2021 2021
Emtriva emtricitabine HIV, AIDS 2003-07-02 2021 2016
Flolan epoprostenol sodium pulmonary hypertension 1995-09-20 GlaxoSmithKline expired expired
Hepsera adefovir dipivoxil hepatitis B (HBV) 2002-09-20 2014 2011
Letairis ambrisentan pulmonary arterial hypertension 2007-06-15 GlaxoSmithKline 2015 2015
Lexiscan regadenoson myocardial perfusion imaging 2008-04-10 Astellas 2019 2020
Macugen pegaptanib sodium solution age-related macular degeneration 2004-12-17 OSI and Pfizer 2017 2017
Ranexa ranolazine angina 2006-01-27 Hoffmann � La Roche 2019 2019
Tamiflu oseltamivir phosphate influenza 1999-10-27 Hoffmann � La Roche 2016 2016
Truvada emtricitabine and tenofovir HIV, AIDS 2004-08-02 2021 2018
Viread tenofovir HIV, AIDS, Hepatitis-B 2001-10-26 2017 2018
Vistide cidofovir CMV retinitis 1996-06-26 Pfizer 2010 2012

Product pipeline
Timetable of mergers and acquisitions :
Drug Name Description Potential Indication Testing Phase
Integrase Fixed-dose Regimen "Quad" elvitegravir/FTC/TDF/cobicistat HIV/AIDS Phase III
Truvada/TMC 278 Fixed-dose Regimen Viread, Emtriva, and TMC 278 HIV/AIDS Phase III
Elvitegravir integrase inhibitor HIV/AIDS Phase III
Cobicistat (GS-9350) Pharmacokinetic enhancer HIV/AIDS Phase III
Tegobuvir (GS 9190) polymerase inhibitor Hepatitis C Phase II
Cicletanine antihypertensive Pulmonary Arterial Hypertension Phase II
Aztreonam inhalation solution Bronchiectasis Phase II
Ranolazine late sodium current inhibitor Coronary Artery Disease/Diabetes Phase II
GS 9256 protease inhibitor Hepatitis C Phase II
GS 9310/11 inhaled fosfomycin/tobramycin Cystic Fibrosis/Chronic Obstructive Pulmonary Disease Phase II
GS 9667 (formerly CVT-3619) partial A1 adenosine agonist Diabetes/Dyslipidemia terminated
GS 7340 nucleotide HIV/AIDS Phase I
GS 9451 protease inhibitor Hepatitis C Phase I
GS 5885 NS5A inhibitor Hepatitis C Phase I
GS 9620 TLR-7 agonist Hepatitis C/Hepatitis B Phase I
GS 6201 (formerly CVT-6883) A2B adenosine antagonist Pulmonary diseases Phase I
GS 6620 nucleotide polymerase inhibitor Hepatitis C Phase I
GS 9669 non-nucleotide polymerase inhibitor Hepatitis C pre-clinical
GS 9411 epithelial sodium channel blocker Pulmonary diseases Phase I
CVT-10216 ALDH-2 inhibitor drug addiction pre-clinical
Tecadenoson selective A1 adenosine receptor atrial fibrillation terminated
Perfan enoximone heart failure Phase III
GS 9219 nucleotide analogue non-Hodgkin’s lymphoma and chronic lymphocytic leukemia Phase I
GS 8374 protease inhibitor HIV/AIDS pre-clinical
GS 424020 prodrug of desisobutryl-ciclesonide and salmeterol asthma and chronic obstructive pulmonary disease pre-clinical
GS 9148 nucleotide analog, phosphonomethoxy-2'-fluoro-2', 3'-dideoxydidehydroadenosine HIV/AIDS pre-clinical
GS 9131 prodrug of GS 9148 HIV/AIDS pre-clinical
GS 9224 integrase inhibitor HIV/AIDS pre-clinical
GS 6624 humanized monoclonal antibody idiopathic pulmonary fibrosis and advanced solid tumors Phase I
CAL-101 PI3K Delta selective inhibitor Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma Phase I
CAL-263 PI3K Delta selective inhibitor inflammatory diseases Preclinical
CAL-120 PI3K Delta selective inhibitor inflammatory diseases and oncology Preclinical
CAL-129 PI3K Delta selective inhibitor inflammatory diseases and oncology Preclinical
CAL-253 PI3K Delta selective inhibitor inflammatory diseases and oncology Preclinical

Companies of the NASDAQ-100 index

Activision Blizzard * Adobe * Akamai * Altera * Amazon.com * Amgen * Apollo Group * Apple * Applied Materials * Autodesk * ADP * Baidu * Bed Bath & Beyond * Biogen Idec * BMC Software * Broadcom * C.H. Robinson * CA, Inc. * Celgene * Cephalon * Cerner * Check Point * Cintas * Cisco * Citrix * Cognizant * Comcast * Costco * Dell * Dentsply * DirecTV * Dish Network * eBay * Electronic Arts * Expedia * Expeditors International * Express Scripts * Fastenal * First Solar * Fiserv * Flextronics * FLIR Systems * Foster Wheeler * Garmin * Genzyme * Gilead Sciences * Google * Henry Schein * Hologic * Illumina * Infosys * Intel * Intuit * Intuitive Surgical * J.B. Hunt * Joy Global * KLA-Tencor * Lam Research * Liberty Media * Life Technologies * Linear Technology * Logitech * Marvell * Mattel * Maxim Integrated Products * Microchip Technology * Microsoft * Millicom * Mylan * NetApp * News Corporation * NII * Nvidia * O'Reilly Automotive * Oracle * Paccar * Patterson Companies * Paychex * Priceline.com * Qiagen * Qualcomm * Research In Motion * Ross Stores * SanDisk * Seagate * Sears * Sigma-Aldrich * Staples * Starbucks * Stericycle * Symantec * Teva Pharmaceutical * Urban Outfitters * VeriSign * Vertex Pharmaceuticals * Virgin Media * Vodafone * Warner Chilcott * Wynn Resorts * Xilinx * Yahoo!



Privacy | Sitemap | Micra Hosting | USA Yellow Pages